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ABSTRACT
Objectives: Drug interactions, poor adherence to
medication and high-risk sexual behaviour may occur
in individuals with HIV using recreational drugs. Thus,
we aimed to assess the prevalence of recreational
drugs use and to explore its clinical impact in HIV
patients on treatment.
Methods: Observational, cross sectional, study
conducted in a 700 bed university hospital, Barcelona,
Spain. A total of 208 adults living with HIV on
treatment were included. A questionnaire was
administered by clinical pharmacists, including
evaluation of sociodemographic variables, past
12-month drug consumption, adherence to
antiretrovirals (Simplified Medication Adherence
Questionnaire) and high-risk sexual behaviour
(condomless sex/multiple partners). Additional data
were obtained from clinical records. Recreational drug-
antiretroviral interactions were checked in reference
databases. Prevalence was calculated for 5% precision
and 95% CI. Crude and adjusted binary logistic
regressions were performed to identify associations
between recreational drug use and adherence
problems, and between recreational drug use and high-
risk sexual behaviour.
Results: From the overall sample, 92 participants
(44.2%) consumed recreational drugs over the past
1 year. Of these, 44 (48.8%) had used different types
of recreational drugs in this period. We detected 11
recreational substances, including sildenafil and
nitrites. The most consumed drugs were: cannabis
(68.5%), cocaine (45.5%), nitrites (31.5%), sildenafil
(28.3) and ecstasy (19.6%). Relevant interactions
occurred in 46 (50%) of the individuals consuming
drugs. Recreational drug consumption was found to be
related to adherence problems with antiretrovirals (OR:
2.51 (95% CI 1.32 to 4.77) p=0.005) and high-risk
sexual behaviour (OR: 2.81 (95% CI 1.47 to 5.39)
p=0.002).
Conclusions: Recreational drugs are frequently used
by HIV patients on treatment. Classical drugs and new
substances consumed in sexual context are usual.
Recreational drug consumption interferes with several
clinical outcomes, including potentially relevant
interactions between drugs and antiretrovirals,
adherence problems and high-risk sexual behaviour.
Thus, there is the urgent need of implementing patient-
centred care involving recreational drug consumption.
INTRODUCTION
HIV continues to be a major public health
challenge, with two million new infections
globally in 2014.1 In Spain, about 150 000
people were estimated to live with HIV in
2015.2 The incidence rate was 9.34 cases per
100 000 inhabitants in 2014, higher than the
average incidence in the European Union.3
Among the new cases in Spain, 53.9% were
men who have sex with men (MSM), fol-
lowed by heterosexuals (26.0%) and inject-
ing drug users (3.4%).3 In contrast with the
Strengths and limitations of this study
▪ We studied the prevalence of recreational drug
consumption in people living with HIV on treat-
ment and its association with relevant clinical
outcomes.
▪ The high prevalence and specific patterns of rec-
reational drug use found in our study may vary
across countries according to sociodemographic
and lifestyle characteristics.
▪ Relevant theoretical interactions between recre-
ational and antiretroviral drugs occurred in half
of the patients using recreational drugs. To what
extent these interaction may lead to clinically
relevant interactions is uncertain.
▪ Adherence problems with the antiretroviral treat-
ment in the individuals consuming recreational
drugs may result in treatment failure depending
on the recreational drug patterns of use, the
degree of non-compliance and the pharmacoki-
netic profile of antiretrovirals.
▪ Owing to the cross-sectional nature of the study,
causality cannot be totally inferred.
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spread of HIV transmission, the effectiveness of highly
active antiretroviral therapy (HAART) has translated
into a decrease in mortality by 42% since 2004 globally.1
Mortality reduction in people living with HIV
(PLWHIV), along with improved tolerability of newer
drugs, have led to consider HIV as a chronic condition.4
Consequently, there is a need for a clinical approach in
which care of PLWHIV is tailored to each individual’s
needs. This implies addressing conventional concerns
such as linkage to care, and emerging issues such as rec-
reational drug consumption.
It is estimated that almost a quarter of the adult
population in Europe have tried illicit drugs at some
point in their lives, being cannabis, cocaine, ampheta-
mines and ecstasy the most consumed in the general
population.5 Some studies have found a great propor-
tion of recreational drug consumption in groups at risk
or with great prevalence of HIV infection, especially for
MSM, in countries such as the USA.6 7 In Europe, the
EMIS study reported data on recreational drug use in
MSM, showing poppers, cannabis and ‘sex drugs’ as
especially prevalent.8 As for Spain, this relevant study
showed cannabis, poppers, sildenaﬁl, cocaine and
3,4-methylenedioxymethamphetamine (ecstasy) as the
most consumed substances over the past 12 months.9
However, only 23% of the individuals in Spain reported
being HIV-positive, as this was not the target group of
the study.8 9 Unlike the case of injecting drug users,
with clear evidence of poor HIV-related outcomes and
speciﬁc recommendations,10 interest in recreational
drugs is recent in the HIV ﬁeld. A previous, systematic
review found 12 articles reporting prevalence data on
recreational drug use in PLWHIV in Europe.11 Relevant
use of recreational drugs was found in these studies.
Moreover, polydrug consumption, deﬁned as the use of
various drugs over a period of time, was about 50% in
some cases. However, most of the included studies col-
lected data on a limited number of recreational drugs
as they primarily focused on other topics and, there-
fore, methods varied greatly across them. Also, partici-
pants were included regardless of receiving HAART in
most studies. According to the review results, with the
exception of extensive, methodologically sound studies
in countries such as the UK,12 little is known about the
use of recreational drugs in many European countries,
including Spain.
Consumption of recreational drugs may have relevant
clinical consequences for PLWHIV who are on HAART.
First, its use has been described as a factor contributing
to non-adherence to HAART.13 Recreational drug use
may lead to low disease awareness, temporary cognitive
impairment (depending on the substance) and may
interfere with daily routine, which would be related to
adherence problems.13 Second, interactions between
recreational drugs and HAART may appear and lead to
potential toxic effects or insufﬁcient antiretroviral
plasma concentrations.14 Drug efﬂux transporters and
cytochrome P450 (CYP) are the main factors apparently
involved.15 Additionally, adherence problems are known
to appear when individuals prefer not to take their anti-
retroviral medication in order to prevent these potential
interactions.16 Third, recreational drug consumption
could be associated with a high-risk sexual behaviour
potentially leading to the acquisition of sexual transmit-
ted diseases (STD) in PLWHIV using drugs. For
example, recent results from the ASTRA study showed
the independent relationship between increasing poly-
drug use and increasing prevalence of condomless sex
in HIV-diagnosed MSM in London, 85% of whom were
under HAART.12 This potential association should be
emphasised since the prevalence of chemsex, a term
used to describe sexual relationships under the inﬂu-
ence of certain psychoactive substances,17 has become
increasingly popular in certain areas over the past few
years.
Despite the potential clinical impact of recreational
drug issues, guidelines on HIV antiretroviral therapy
have poorly incorporated these elements.11 Guidelines
tend to include general claims but usually lack speciﬁc
recommendations. This could be explained as many of
the efforts in this ﬁeld have focused on studying the
association between recreational drug use and the risk
of being infected with HIV11 18 19 rather than assessing
the impact of recreational drugs on people already
living with HIV. Clinicians, researchers and policymakers
may not be fully aware of the real magnitude of the
problem since both the prevalence and the clinical
impact of recreational drug use on PLWHIV is unclear,
especially referring to those people on treatment. This is
especially relevant for countries with very scarce data on
this topic; such is the case of Spain.
Thus, the aim of the current study was to examine the
prevalence of recreational drug consumption on a repre-
sentative sample of adult PLWHIV on HAART, and also
to explore the clinical impact of these drugs at three
levels: adherence to medication, interactions between
recreational drugs and HAART and high-risk sexual
practices.
METHODS
Study design
This hospital-based, observational, cross-sectional study
was conducted in a 700 bed University Hospital,
between April 2015 and December 2015. This reference
hospital services a local population of about 400 000
people in Barcelona (Spain), including 1500 adult
PLWHIV on HAART.
Sample and procedures
The sample included non-institutionalised adults over
18 years old living with HIV and who were on HAART at
the time of the interview. Individuals with severe cogni-
tive decline, with language barriers, needing a legal rep-
resentative, starting their HAART medication since the
past 30 days or already enrolled in other studies were
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considered not eligible. Participants were recruited on
clinical visits to the Hospital Outpatients Pharmacy
during the dispensing process (Monday–Friday; 08:00–
15:00) to maximise the access and quality of the
pharmacist–patient interaction. All interviewers were
experienced hospital pharmacists who had participated
in the questionnaire design. The ﬁnal response rate was
89.3% (from a total of 233 individuals invited to partici-
pate). The ﬁnal analysis consisted of 208 participants.
Data collection and variable definitions
Data were obtained from a short survey questionnaire
administered to the participants by specialist clinical
pharmacists. This questionnaire focused on recreational
drug consumption, adherence to medication, sexual
behaviour and speciﬁc sociodemographic information.
Additionally, participants were informed that supple-
mentary information would be collected from electronic
clinical records. These supplementary data included
variables related to the HIV condition at the time of the
interview: HAART, previous viral load, previous CD4 cell
count, time on treatment, time from HIV diagnosis,
comorbidities and medication other than HAART. Last
viral load and last CD4 cell count referred to results
from blood tests conducted over the past 4 weeks from
the questionnaire response; last viral load category
‘undetectable’ was deﬁned as <20 copies/mL; comorbid-
ities included all chronic conditions obtained from
primary care/hospital clinical records; medication
included all chronic medication other than HAART
obtained from primary care/hospital clinical records.
Sociodemographic variables included age, gender, edu-
cational level, marital status, country of birth, income,
urbanicity (10 000+ inhabitants was considered urban),
employment status, HIV transmission route, use of clas-
sical IV drugs (heroin, cocaine, morphine) and alcohol
consumption. Unhealthy alcohol consumption was
assessed through a single screening question ‘How many
times in the past year have you had X or more drinks in
a day?’ (where X was ﬁve for men and four for women,
and a response of one or more was considered
positive).20
As for recreational drug consumption, we used one
question assessing the use of certain substances over the
past 12 months. There is evidence that the use of a
single question for this purpose is valid for screening
and preliminary evaluation of the use of substances of
abuse compared with long questionnaires.20 The list of
drugs included cannabis, cocaine, amphetamines
(including crystal methamphetamine), ecstasy,
γ-hydroxybutyric acid (GHB), ketamine, mephedrone,
lysergic acid diethylamide (LSD), erection enhancing
medication (eg,: sildenaﬁl) and nitrites (poppers). A list
of frequently-used synonyms was also used to ensure
drugs could easily be identiﬁed by patients. Adherence
to HAART was assessed by means of the Simpliﬁed
Medication Adherence Questionnaire (SMAQ), a 6-item,
validated tool.21 High-risk sexual behaviour was
evaluated with two questions according to the previous
literature:12 22 23 a ﬁve-categories Likert question relating
to the frequency of condom use in sexual intercourse,
and a question on the number of sexual partners (≥10)
over the past 12 months. After information was col-
lected, theoretical recreational drug-HAART interactions
were checked with daily-practice interaction databases:
‘http://www.hiv-druginteractions.org’ by the University
of Liverpool24 and ‘Drug interaction Search’ by
Micromedex Solutions, 2015 Truven Health Analytics.
Statistical analysis
Sample size was calculated with the GRANMO calcula-
tor25 on the basis of determining the recreational drug
consumption prevalence in our population group. We
considered an approximate number of 1500 PLWHIV on
treatment in our hospital, 15% prevalence of drug use
in the Spanish general population26 5% precision and
95% CI. In order to ensure statistical robustness and
facilitate additional statistical data analyses we ﬁnally
considered an inﬁnite sample for calculation purposes,
which resulted in a minimum needed sample size over
200 participants.
Frequencies, proportions, range, mean, SD, CIs and
cross tabulations were applied for descriptive analysis. χ2
Test, Fisher’s exact test and t-test were used to measure
differences in prevalence of sociodemographic and clin-
ical variables across recreational drug consumption. χ2
Test was also used to assess differences in adherence to
ART medication and measures of sexual risk behaviour
across recreational drug consumption. Crude and
adjusted binary logistic regressions were used to
examine the relationship between recreational drug con-
sumption and the existence of potential problems
regarding adherence to HAART. Variables used for
bivariate models considered those that are supposed to
impact on adherence according to the literature: age,
gender, education level, marital status, household
income, employment, country, alcohol consumption and
pill burden. The multivariate logistic regression model
included those variables with an association in the bivari-
ate analyses deﬁned as p<0.1 (gender, age, country of
origin, education level, recreational drug consumption).
Results are reported as unadjusted and adjusted ORs
with 95% CI. Analogous procedures were used to
examine the association between recreational drug con-
sumption and high-risk sexual behaviour, deﬁned as
having 10 or more sexual partners over the past
12 months and/or declaring condomless sex during this
period. In this case, variables in the bivariate models
included age, gender, education level, marital status,
household income, employment, country, alcohol con-
sumption and transmission route. In its corresponding
multivariate analysis model, apart from the aforemen-
tioned statistical procedures (excluding marital status
only), we excluded additional variables that measured
the same construct as other variables of the model
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(gender, alcohol and employment were excluded).
Analyses were performed with IBM SPSS statistics V.19.
Ethics statement
The study was approved by the reference Clinical
Research Ethics Committee. Additionally, an independ-
ent community representative reviewed the protocol to
ensure patient-oriented evaluation and suitability of the
study. Written informed consent was obtained from all
participants, including the acceptance of data collection
from the questionnaire and the revision of clinical
records. All investigators worked according to the princi-
ples expressed in the Declaration of Helsinki.
RESULTS
The study population consisted of 208 participants.
Participants mean age was 46.8 years (SD: 10.4 years;
range: 24–75 years). Practically all individuals lived in
urban areas, with 80% of them being men. Regarding
their HIV management, 83.2% had undetectable HIV
viral load and 35.6% were receiving a single-tablet treat-
ment at the time of the interview. A summary of the full
list of sociodemographic and clinical data is available at
table 1.
As for recreational drug consumption, 92 (44.2%) par-
ticipants declared having consumed drugs over the past
12 months (table 2). Of them, 44 (47.8%) had taken
two or more drugs during that period. As for the drugs
consumed, we found 11 recreational drugs, with canna-
bis (68.5%), cocaine (45.5%), poppers (31.5%) and
erection enhancing substances (28.3%) being the most
consumed drugs.
Moderate-to-severe, potential and theoretical interac-
tions were found in 46 participants, half of the patients
consuming drugs during the past 12 months, as a result
of the search in interactions databases with respect to
HAART regimens and recreational drugs consumed by
these individuals. HAART involved in these interactions
were: ritonavir-boosted protease inhibitors, some non-
nucleoside reverse transcriptase inhibitors and cobicistat-
boosted elvitegravir. All recreational drugs except for
LSD and poppers were found to have relevant potential
interactions in some individuals. Interactions distribu-
tion across recreational drugs is presented at table 3.
Problems with adherence were found in 64.1% of the
individuals using recreational drugs and in 44.8% of the
non-users. Condomless sex and having 10+ different
sexual partners during the past year occurred in 49
(53.3%) and 31 (33.7%) individuals using drugs,
respectively (table 4).
Table 5 shows the crude and adjusted logistic regres-
sion ORs for the association between recreational drug
consumption and the existence of adherence problems
with HAART. After adjusting for covariates, recreational
drug consumption and educational level were revealed
to be associated with adherence problems (OR: 2.51
(95% CI 1.32 to 4.77) p=0.005; OR (secondary vs
primary level): 2.56 (95% CI 1.07 to 6.14) p=0.035,
respectively). Also, recreational drug consumption, age
and income was associated with sexual risk behaviour
after adjusting for covariates (OR: 2.81 (95% CI 1.47 to
5.39) p=0.002; OR: 0.96 (95% CI 0.93 to 0.99) p=0.032;
OR: 0.48 (95% CI 0.25 to 0.91) p=0.025, respectively).
There were no missing data for recreational drug use,
clinical variables and most sociodemographic variables.
Information on employment status and education level
was missing in 3.4% and 6.6% of the participants,
respectively. We did not impute these variables as we
could not guarantee whether these data were missing at
random.
DISCUSSION
Our study found a relevant prevalence of recreational
drug use among PLWHIV on HAART in Spain. A great
proportion of the patients consuming recreational drugs
had potentially severe interactions between these drugs
and their HAART. Moreover, relationships between the
use of drugs and other negative clinical outcomes such
as problems with adherence to HAART and high-risk
sexual behaviour have been detected, which are also
essential for better understanding and management of
drug consumption in PLWHIV.
Few studies have previously focused on recreational
drug use in PLWHIV in Europe, especially in countries
such as Spain. The ASTRA study included 2248 MSM
living with HIV from eight outpatient clinics in the UK,
with 85% on HAART.12 In that case, they found a preva-
lence of recreational drug consumption in the past
3 months of about 51%. Our results, although slightly
lower than that in the ASTRA Study, conﬁrm the high
prevalence of recreational drug consumption in a spe-
ciﬁc area of Spain. Apart from the prevalence of use, we
found certain differences compared with the ASTRA
study. For example, in our study cannabis was the most
frequent drug, doubling ﬁgures of nitrites, the most
common drug in the ASTRA study. In fact, cannabis and
cocaine, the drugs most frequently used in the general
population in Spain, were found to be the most con-
sumed in our study.5 We also found a high prevalence of
sex-related drug use, including nitrites and erection
enhancing medication, such as sildenaﬁl. Previous
studies in PLWHIV reported high prevalence ﬁgures on
these drugs in several European countries that conﬁrm
the idiosyncrasy of drug consumption in this popula-
tion.12 27 28 Coadministration of sildenaﬁl and nitrites is
contraindicated because of their increased cardiovascu-
lar effects,29 so that interviewers provided information
to individuals who reported using both substances
together.
It is worth highlighting the number of different recre-
ational drugs detected in the study, along with the preva-
lence of individuals who consumed several drugs over
the past 12 months. We detected 11 recreational drugs,
9 of them with prevalence over 10% among the
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Table 1 Description of the sample
Total sample
(n=208)
Non-recreational drug
users (n=116)
Recreational drug
users (n=92) p Value
Sociodemographic variables
Age (mean, SD) (years) 46.8 (10.4) 48.6 (10.8) 44.5 (9.5) 0.004
Gender (n, %) 0.001
Male 167 (80.3%) 84 (72.4%) 83 (90.2%)
Female 41 (19.7%) 32 (27.6%) 9 (9.8%)
Education (n, %) 0.042
≤Primary 51 (26.3%) 36 (33.0%) 15 (17.6%)
Secondary 92 (47.4%) 49 (45.0%) 43 (50.6%)
≥Tertiary 51 (26.3%) 24 (22.0%) 27 (31.8%)
Country of origin (n, %) 0.045
Spain 129 (62.0%) 79 (68.1%) 50 (54.3%)
Other 79 (38.0%) 37 (31.9%) 42 (68.1%)
Location (n, %) 1.000
Rural 5 (2.4%) 3 (2.6%) 2 (2.2%)
Urban 203 (97.6%) 113 (97.4%) 90 (97.8%)
Employment (n, %) 0.758
Working 140 (69.7%) 78 (70.9%) 62 (68.1%)
Unemployed 61 (30.3%) 32 (29.1%) 29 (31.9%)
Marital status (n, %) 0.050
Married/cohabiting 96 (46.2%) 61 (52.6%) 35 (38.0%)
Single 112 (53.8%) 55 (47.4%) 57 (62.0%)
Household income (n, %) 0.071
≤Median 105 (50.5%) 52 (44.8%) 53 (57.6%)
>Median 103 (49.5%) 64 (55.2%) 39 (42.4%)
Alcohol consumption (n, %) 0.001
Non-consumer 120 (57.7%) 79 (68.1%) 41 (44.6%)
Consumer 88 (42.3%) 37 (31.9%) 51 (55.4%)
Classical IV drugs (n, %) -
Non-user 206 (99.0%) 116 (100%) 90 (97.8%)
User 2 (1.0%) - 2 (2.2%)
Transmission route (n, %) 0.001
Heterosexual/IV drugs use/transfusion 87 (41.8%) 61 (52.6%) 26 (28.3%)
MSM 121 (58.2%) 55 (47.4%) 66 (71.7%)
Clinical variables
ART pill burden (n, %) 0.383
1 pills/day 74 (35.6%) 39 (33.6%) 35 (38.0%)
2 pills/day 67 (32.2%) 42 (36.2%) 25 (27.2%)
≥3 pills/day 67 (32.2%) 35 (30.2%) 32 (34.8%)
Viral load (n, %) 0.358
Undetectable 173 (83.2%) 99 (85.3%) 74 (80.4%)
Detectable 35 (16.8%) 17 (14.7%) 18 (19.6%)
CD4 cell count (n, %) 0.054
<500 cells/μL 53 (25.5%) 36 (31.0%) 17 (18.5%)
≥500 cells/μL 155 (74.5%) 80 (69.0%) 75 (81.5%)
Time on treatment (mean, SD) 10.4 (7.1) 12.0 (7.2) 8.3 (6.4) 0.001
Time diagnosed (mean, SD) 12.8 (8.2) 14.5 (8.1) 10.7 (7.8) 0.001
Other comorbidity (n, %) 0.854
No 36 (17.3%) 21 (18.1%) 15 (16.3%)
Yes 172 (82.7%) 95 (81.9%) 77 (83.7%)
Other medication (n, %) 0.381
No 72 (34.6%) 37 (31.9%) 35 (38.0%)
Yes 136 (65.4%) 79 (68.1%) 57 (62.0%)
Frequencies, proportions, means and SDs are displayed. χ2 Test (for 2×N tables) and t-test (for continuous variables) were performed to
compare across recreational drug consumption (also, Fisher’s exact test was used for variables ‘location’ and ‘classical IV drugs’). Variables:
age, time on treatment and time diagnosed are expressed in years. Employment category ‘unemployed’ included unemployed and inactive
population such as homemakers and retired; Marital status category ‘single’ included: single, separated, divorced and widowed; Household
income ‘median’ was €16 000/year; Classical IV drugs included heroin, cocaine, morphine; Viral load category ‘undetectable’ was defined as
<20 copies/mL.
ART, antiretroviral therapy.
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individuals taking drugs. Some of these drugs can be
considered club drugs, such as ecstasy, GHB, ampheta-
mines, speed and ketamine. Moreover, we found a rele-
vant proportion of participants reporting drugs included
in the deﬁnition of ‘chemsex’: GHB, metamphetamines
or mephedrone.17 Apart from interactions, chemsex has
been associated with high-risk sexual practices, including
condomless sex or slamming, which involves injecting
drugs such mephedrone or GHB.11 14 17 To what extent
these drugs can lead to addiction and abuse needs
further study, which should take into account some
related sociocultural issues such as the widespread use of
geo-sexual networking apps.
The prevalence of relevant potential interactions
between recreational drugs and HAART in Spain is
unclear to date. The results of our study revealed a great
proportion of relevant potential interactions in PLWHIV
on treatment. These interactions involved 10 different
recreational drugs and 3 antiretroviral groups (ritonavir-
boosted PIs, non-nucleoside reverse transcriptase
inhibitors and cobicistat-boosted integrase inhibitors).
Although several mechanisms have been described in
the literature, most of the relevant interactions between
recreational drugs and HAART are known to occur
through the CYP metabolic pathway.14 30 Moreover, most
interactions described in the literature result in accumu-
lation of recreational drugs or their toxic metabolites,
leading to potential risk of adverse effects by these sub-
stances. As expected, that was the case in our study.
However, we also found six individuals with an inter-
action between cannabis and atazanavir, which is known
to decrease blood levels of atazanavir below its thera-
peutic range in 50% of the individuals on treatment
with atazanavir using cannabis.24
In contrast with issues such as poor tolerability or
poor adherence to medication, it may seem that poten-
tial severe interactions between recreational drugs and
HAART need to be reconsidered in future clinical
approaches. We hypothesise two main reasons leading to
this situation: unawareness of the relevance of these
interactions by clinicians and, especially, the fact that
drug use can be an undisclosed issue by patients. In fact,
Table 2 Prevalence of past 12-month recreational drug
consumption among individuals consuming recreational
drugs (n=92)
Number of
individuals (%)
Mean (min–max;
days)
Type of drug
Cannabis 63 (68.5) 164.5 (1–365)
Cocaine 40 (45.5) 14.9 (1–156)
Poppers 29 (31.5) 14.7 (1–52)
Sildenafil 26 (28.3) 12.6 (1–104)
Ecstasy 18 (19.6) 5.9 (1–24)
GHB 14 (15.2) 12.7 (1–100)
Amphetamines 11 (12.0) 5.6 (1–20)
Speed 11 (12.0) 13.45 (2–52)
Ketamine 9 (9.8) 6.1 (1–24)
Mephedrone 4 (4.3) 16.3 (1–50)
LSD 1 (1.1) 1 (1–1)
Number of drugs
1 48 (52.2) –
2 14 (15.2) –
3 10 (10.9) –
4 6 (6.5) –
5 5 (5.4) –
6+ 9 (9.8) –
Values calculated for the group of individuals taking recreational
drugs. Frequencies, proportions, means and ranges are displayed.
‘Mean’ refers to the average consumption of each drug over the
past 12 months.
Amphetamines, include crystal meth; GHB, γ-hydroxybutyric acid;
LSD, lysergic acid diethylamide; MDMA,
3,4-methylenedioxymethamphetamine (commonly known as
ecstasy).
Table 3 Past 12-month, potential, relevant interactions between recreational drugs and antiretrovirals (n=46)
Ritonavir boosted PI NNRTI
Cobicistat
boosted
INSTIs
Atazanavir/r Darunavir/r Lopinavir/r Efavirenz Etravirine Nevirapine Rilpivirine Elvitegravir/c
Amphetamines – – – – – – – 3
Cannabis 6 – – – – – – –
Cocaine 4 8 2 2 3 1 12 7
Ecstasy – 4 – – – – – –
GHB 1 2 – – – – – –
Ketamine – 2 1 1 1 – – 1
Mephedrone – 1 – – – – – –
Speed 1 1 – 2 – – – 3
Sildenafil 1 4 – 2 5 1 – 2
Potential, relevant interactions between HAART regimens and recreational drugs used over the past 12 months were assessed according to
reference databases (frequencies are displayed). The table shows interactions in 46 individuals from the 92 recreational drug users.
Results in the table refer to the number of participants with each interaction. No interactions were found in consumers of poppers and LSD.
GHB, γ-hydroxybutyric acid; HAART, highly active antiretroviral therapy; INSTIs, integrase strand transfer inhibitor; LSD, lysergic acid
diethylamide; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.
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a recent analysis by Daskalopoulou et al31 of participants
on HAART from the ASTRA study found very similar
prevalence of recreational drug consumption across dif-
ferent HAART regimens, suggesting that clinicians do
not consider drug use as a relevant issue in HAART
selection. The authors also claim for the need of non-
judgmental attitudes by healthcare providers when dis-
cussing drug use along with the beneﬁts of community
peer-led initiatives.31
Adherence to HAART is essential for controlling HIV
infection. The prevalence of individuals with adherence
problems in our study was 64.1% in those people using
recreational drugs and 44.8% in non-users. The results
of the multivariate logistic regression showed a statistic-
ally signiﬁcant relationship between recreational drug
use and lower adherence rates. Our results agree with
the ones of the ASTRA study, in which recreational drug
use was associated with lower adherence rates.12 Also, as
in the ASTRA study, prevalence of undetectable viral
load in the group consuming recreational drugs on
HAART was above 80%, which highlights that consum-
ing recreational drugs is not necessarily related to adher-
ence problems leading to clinical complications.12 It is
estimated that a minimum adherence rate of about 85%
is needed to suppress RNA in about 80% of patients on
HAART treatment.32 As a consequence, the number of
missed doses along with the pharmacokinetic proﬁle of
antiretrovirals may modulate the ﬁnal impact of treat-
ment efﬁcacy.
From a behavioural perspective, several aspects should
be considered when interpreting the association
between recreational drug consumption and adherence
problems. Individuals consuming recreational drugs may
be concerned by severe potential intoxications or
adverse effects due to interactions between recreational
drugs and medicines. This concept is known as ‘inter-
active toxicity belief’.16 Thus, some people may antici-
pate, delay or miss their HAART medication, which may
partly explain the results found in our study. For
example, Kalichman et al16 found that 35% of PLWHIV
on treatment intentionally miss doses when they are
using drugs, being those individuals with interactive tox-
icity belief at greater risk. Apart from intentional non-
adherence, temporary cognitive impairment due to the
use of recreational drugs may interfere with memory or
routine activities and eventually impact negatively on
adherence to HAART.13 To what extent each compo-
nent, intentional versus non-intentional non-adherence,
affects our results is unknown and should be subject of
further investigations.
Finally, our results showed a clear association between
the past 12-month recreational drug consumption and
high-risk sexual behaviour, including condomless-sex and
multiple sexual partners. Caution should be exercised in
the interpretation of this result. High-risk sexual behav-
iour may lead to a greater risk of acquiring sexually trans-
mitted infections by individuals consuming recreational
drugs. Our results expand and complement the evidence
found in previous studies which found a clear association
between the use of recreational drugs and several mea-
sures of high-risk sexual practices, such as unprotected
anal intercourse, group sex or multiple sexual part-
ners.12 33 Moreover, risk of HIV transmission to other
sexual partners would be low as most individuals in the
study had suppressed HIV viral load, which relates to a
minimal transmission risk according to the results found
in the PARTNER study.34 There is however, the risk of
HIV transmission in the case of individuals with detect-
able HIV viral load. Since alcohol and drug use can be
relatively common during unprotected sexual relation-
ships in speciﬁc population groups, interventions would
also be justiﬁed to prevent HIV transmission.27 Thus, our
results underline the need of comprehensive interven-
tions aiming to prevent new HIV transmissions in speciﬁc
population groups and also to reduce sexually transmit-
ted infections in PLWHIV using recreational drugs. As
aforementioned, further studies should continue explor-
ing the risks of chemsex, as this may involve polydrug use
and particularly high-risk sexual behaviour along with
possible addictive-related concerns.12 14 17
Table 4 Outcomes on adherence to ART medication and measures of sexual risk behaviour over the past 12 months
Total sample (n=208)
Non-recreational drug
users (n=116)
Recreational drug
users (n=92) p Value
Adherence to ART 0.004
Good adherence 97 (46.6%) 64 (55.2%) 33 (35.9%)
Poor adherence 111 (53.4%) 52 (44.8%) 59 (64.1%)
Sexual intercourse 0.001
Condom-protected sex 129 (62.0%) 86 (74.1%) 43 (46.7%)
Condomless sex 79 (38.0%) 30 (25.9%) 49 (53.3.0%)
Sexual partners 0.001
<10 164 (78.8%) 103 (88.8%) 61 (66.3%)
≥10 44 (21.2%) 13 (11.2%) 31 (33.7%)
Frequencies and proportions are displayed. χ2 Tests for 2×2 tables were performed to compare across recreational drug consumption.
Adherence to ART was measured with the SMAQ questionnaire; Sexual intercourse category ‘condomless sex’ refers to having any/all sexual
intercourse without condom over the last 12 months; Sexual partners refers to the count of different sexual partners over the past 12 months.
ART, antiretroviral therapy; SMAQ, Simplified Medication Adherence Questionnaire.
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Table 5 Multivariable logistic regression results
Adherence model Sexual risk model
OR crude (95% CI) p Value AOR (95% CI) p Value OR crude (95% CI) p Value AOR (95% CI) p Value
Gender
Male 1.00 1.00 1.00 – –
Female 1.91 (0.93 to 3.89) 0.076 1.91 (0.85 to 4.30) 0.117 0.35 (0.16 to 0.73) 0.006 – –
Age 0.97 (0.94 to 0.99) 0.036 0.97 (0.95 to 1.01) 0.157 0.94 (0.92 to 0.97) 0.000 0.96 (0.93 to 0.99) 0.032
Country of origin
Spain 1.00 1.00 1.00 1.00
Other 1.62 (0.92 to 2.86) 0.095 1.37 (0.72 to 2.63) 0.340 1.66 (0.94 to 2.92) 0.079 1.17 (0.61 to 2.28) 0.636
Education level
≤Primary 1.00 1.00 1.00 1.00
Secondary 2.25 (1.01 to 5.01) 0.047 2.56 (1.07 to 6.14) 0.035 0.45 (0.21 to 0.99) 0.049 0.81 (0.31 to 2.11) 0.810
≥Tertiary 0.99 (0.50 to 1.96) 0.971 0.97 (0.47 to 2.00) 0.936 0.56 (0.28 to 1.13) 0.104 0.66 (0.31 to 1.41) 0.288
Employment
Working 1.00 – – 1.00 – –
Unemployed 0.74 (0.40 to 1.36) 0.331 – – 0.57 (0.31 to 1.06) 0.075 – –
Marital status
Single 1.00 – – 1.00 – –
Married/cohabiting 1.06 (0.62 to 1.83) 0.830 – – 1.10 (0.64 to 1.90) 0.732 – –
Household income
>Median 1.00 – – 1.00 1.00
≤Median 1.36 (0.79 to 2.35) 0.271 – – 0.58 (0.34 to 1.01) 0.054 0.48 (0.25 to 0.91) 0.025
Alcohol consumption
Non-consumer 1.00 – – 1.00 – –
Consumer 1.49 (0.86 to 2.60) 0.157 – – 1.74 (0.99 to 3.03) 0.051 – –
Transmission route
Heterosexual/IV drug use/transfusion – – – – 1.00 1.00
MSM – – – – 2.57 (1.45 to 4.55) 0.001 1.46 (0.71 to 3.02) 0.301
Pill burden
1 ART 1.00 – – – – – –
2+ ART 1.13 (0.64 to 2.00) 0.665 – – – – – –
Recreational drugs
Non-consumer 1.00 1.00 1.00 1.00
Consumer 2.20 (1.26 to 6.86) 0.006 2.51 (1.32 to 4.77) 0.005 3.09 (1.75 to 5.47) 0.000 2.81 (1.47 to 5.39) 0.002
Results refer to univariate and multivariable logistic regression for the total sample.
Results with 95% CI. Age was included as a continuous variable. In the variable ‘transmission route’ heterosexual, IV drug use and transfusion was grouped together due to the small number of
individuals.
AOR, adjusted OR; ART, antiretroviral therapy; MSM, men who have sex with men.
8
Garin
N,etal.BM
J
Open
2017;7:e014105.doi:10.1136/bm
jopen-2016-014105
O
p
e
n
A
c
c
e
s
s
Our study has certain limitations. First, its cross-
sectional nature identiﬁes associations but does not
allow causal relationships to be determined. Second, we
used a self-reported, interviewer-administered, data col-
lection method that could bias the results. Some indivi-
duals may be reluctant to report drug use as it is not
socially accepted and they may fear being judged by
health professionals. Thus, there is the possibility that
the prevalence/frequency of recreational drug use is
underestimated. For the same reason, it could be the
case that some of the PLWHIVs not accepting to partici-
pate in the study had some issues with accepting recre-
ational drug use publicly. Third, our results may only
apply to our geographical area or to very similar ones
(urban areas with same socioeconomic level) in Spain.
Extrapolation of the results to other contexts is not
straightforward as recreational drug patterns are hetero-
geneous across countries in Europe, while differing
recall periods may also make difﬁcult comparisons of
prevalence estimates with other studies. Also, since con-
sumption patterns change with time, results on preva-
lence of use and their impact could differ with ours in
the long term. Another limitation may be the choice of
10 different sexual partners in the past year, which could
lead to potential overestimation of sexual risk behaviour,
especially for MSMs who may have high partner turn-
over. Finally, most drug-recreational drug interaction
databases base their information on theoretically
expected interactions according to metabolic pathways.
Lack of clinical studies on real-life interactions leads to a
useful but imprecise picture on this outcome, potentially
omitting certain interactions not yet described.
In conclusion, prevalence of recreational drug con-
sumption is particularly high in PLWHIV on treatment,
the use of different drugs being relatively frequent.
Furthermore, the results of our study contribute to a
deeper understanding of the impact of recreational
drugs at various levels. First, theoretically relevant inter-
actions occurred in half of the individuals using drugs.
Clinicians should be aware of the most relevant interac-
tions and may adapt antiretroviral therapy in certain
cases according to the pharmacokinetics of the antiretro-
virals and recreational drug patterns of use. Second, rec-
reational drug use was associated with lower adherence
to antiretrovirals and high-risk sexual behaviour, which
may lead to a higher risk of therapy failure and STD
acquisition, respectively. Recreational drug consumption
should be discussed openly between health professionals
and PLWHIV on treatment seeking to clarify both
general and individual recreational drug-related con-
cerns. Further exploration on possible interventions
aiming to decrease negative clinical outcomes related to
recreational drugs are needed to minimise their risks in
PLWHIV on treatment.
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